Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

By sjmartinez • September 2, 2022

Gong J, Thomassian S, Kim S, Gresham G, Moshayedi N, Ye JY, Yang JC, Jacobs JP, Lo S, Nissen N, Gaddam S, Tighiouart M, Osipov A, Hendifar A. Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Sep 2;12(1):15013. doi: 10.1038/s41598-022-19401-3. PMID: 36056179; PMCID: PMC9440135.

Tags: Digestive Diseases, General Internal Medicine, Publications

Related Posts

Secondary Spontaneous Bacterial Peritonitis Prophylaxis Is Associated With a Higher Rate of Infections other than Spontaneous Bacterial Peritonitis in 2 US-Based National Cirrhosis Cohorts

Silvey S, Patel N, O'Leary JG, Jakab SS, Patton H, Rogal S, Markley JD, Cheung R, Patel A, Morgan TR, Bajaj JS. Secondary Spontaneous Bacterial[...]

Widespread Pain Moderates the Response to Centrally-Acting Therapies in an Observational Cohort of Patients With Urologic Chronic Pelvic Pain Syndrome: A MAPP Research Network Study

Schrepf A, Locke K, Moldwin R, Williams DA, Till S, Farrar J, Richard Landis J, Tu F, Rodriguez L, Lai H, Naliboff B, Kutch J,[...]

The 2024 top 10 list of endoscopy topics in medical publishing: an annual review by the American Society for Gastrointestinal Endoscopy Editorial Board

Martinez M, Bartel MJ, Chua T, Dakhoul L, Fatima H, Glessing B, Jensen D, Lara LF, Shinn B, Tadros M, Villa E, Saltzman JR. The[...]